What Is ARA-290?
ARA-290 is a peptide which has been engineered on the basis of the three-dimensional structure of erythropoietin (EPO); it is likewise referred to in the scientific literature as cibinetide or pyroglutamate helix B surface peptide. The molecule is made up of 11 amino acids and was designed using a section of EPO that is linked to non-hematopoietic signalling.
The research interest surrounding ARA-290 is largely connected to receptor biology rather than conventional erythropoietin activity. EPO has distinct signalling functions associated with erythropoiesis and tissue responses, and researchers have investigated whether these activities can be separated at the receptor level. ARA-290 became an experimental tool for studying this alternative signalling system.
For research purposes, this distinction is important. ARA-290 should not simply be treated as a shorter version of EPO. Its structure, receptor interactions and experimental behaviour need to be considered independently.
ARA-290 and the Erythropoietin Receptor System
Erythropoietin belongs to the type I cytokine receptor signalling system. Classical EPO signalling involves the erythropoietin receptor, or EPOR, particularly in erythroid progenitor cells.
Research into the non-hematopoietic actions of EPO led to the proposed involvement of a receptor complex containing EPOR and the β-common receptor, also known as CD131. This complex has been referred to in the literature as the innate repair receptor.
ARA-290 was developed as a peptide ligand intended to investigate this alternative receptor pathway. Experimental studies have therefore examined whether responses attributed to ARA-290 depend on β-common receptor signalling.
The receptor model remains an important part of ARA-290 research, but it should also be interpreted carefully. The proposed physical and functional relationship between EPOR and β-common receptor has been debated, with subsequent research questioning whether a stable direct interaction between the extracellular receptor regions can be demonstrated under experimental conditions.
This makes receptor validation an important consideration when interpreting studies involving ARA-290.
Why the β-Common Receptor Matters in Experimental Studies
CD131, or the β-common receptor, is a shared receptor component involved in signalling by several cytokine receptor systems. Its proposed involvement in ARA-290 activity provides researchers with a way to investigate whether observed cellular responses depend on this receptor component.
One useful experimental approach has been comparison between normal animals and animals lacking the β-common receptor. In a rat and mouse neuropathic pain model, ARA-290 produced changes in tactile and cold allodynia in animals with normal β-common receptor signalling, whereas the response was absent in β-common receptor knockout mice. This type of comparison is useful because it tests receptor dependence rather than relying only on an observed biological response.
More recent experimental work has also examined β-common receptor involvement in mouse models of cerebral ischemia. In that study, suppression of β-common receptor expression reduced the observed effects associated with ARA-290, providing additional experimental evidence for a role of this receptor component.
These studies do not establish a universal mechanism for every biological observation involving ARA-290. Instead, they illustrate how receptor knockout, receptor suppression and pathway measurements can be used to investigate molecular dependence.
ARA-290 Signalling and Cellular Responses
The proposed ARA-290 signalling system is associated with cellular pathways involved in inflammatory signalling, apoptosis, oxidative stress and cellular stress responses.
Experimental studies have investigated changes in inflammatory cytokines, apoptotic markers and oxidative stress indicators following exposure to ARA-290. For example, cell-based research has examined markers including reactive oxygen species, caspase activity and inflammatory signalling in models of chemically induced cellular stress.
These endpoints are useful for mechanistic research because they provide measurable molecular variables rather than relying solely on broad physiological observations.
However, changes in an inflammatory marker or cell-survival pathway should not automatically be interpreted as evidence of a clinical effect. Cellular signalling is highly dependent on the experimental system, peptide concentration, exposure period, cell type and assay conditions.
ARA-290 in Neuropathic Pain Models
Neuropathic pain has been one of the experimental areas in which ARA-290 has been investigated.
An early study used spared nerve injury models in rats and mice to examine tactile and cold allodynia. Researchers compared normal animals with β-common receptor knockout mice to investigate whether the observed response depended on the proposed receptor pathway. The absence of the response in β-common receptor knockout animals provided evidence supporting receptor involvement in that experimental model.
What is important in the case of an educational research article is not merely that ARA-290 was studied in a pain model; the more relevant question is how the model was set up to test the mechanism.
Neuropathic pain models can incorporate behavioural measurements, receptor manipulation, inflammatory markers and tissue analysis. Combining these endpoints allows researchers to examine relationships between receptor signalling, neuroinflammatory processes and observable changes in experimental animals.
The results are specific to the model and cannot be taken as evidence that ARA-290 is a treatment for pain or neuropathy.
Experimental Models Used in ARA-290 Research
ARA-290 research spans several experimental systems.
Cell-based studies have been used to investigate receptor-associated signalling, oxidative stress, apoptosis and inflammatory responses. These models provide controlled conditions for examining molecular pathways but cannot reproduce the complete physiology of an intact organism.
Rodent models have been used to investigate neurological, renal, vascular and inflammatory responses. These experiments allow researchers to examine interactions between tissues, receptor expression and systemic biology. Studies have included nerve injury, cerebral ischemia, renal ischemia-reperfusion and experimental vascular models.
Human research has also appeared in the scientific literature, including investigations involving small-fiber neuropathy. Those studies form part of the published research record but should be distinguished from cell and animal experiments and should not be interpreted as establishing a general human-use application.
Structure and Identity of ARA-290
ARA-290 is structurally distinct from full-length erythropoietin.
The peptide was designed using the structural data from the B-helix area of EPO; descriptions that have already been published refer to it as an 11-amino-acid peptide with a pyroglutamate-containing structure, and the short peptide sequence was intended to mimic the particular structural surface involved in the experimental receptor model rather than to replicate the entire EPO protein.
It is important to take this distinction into account when carrying out analytical research; a peptide obtained from a protein structure cannot be taken to exhibit the same molecular behaviour as the original protein, and in interpreting the experimental material all the factors involving identity, sequence, molecular mass, purity and chemical modifications must be considered.
Consequently, when it comes to laboratory research, it is better to rely on analytical documentation like HPLC and mass spectrometry rather than just on the product name.
Pharmacokinetic Considerations
It has been stated in the literature that ARA-290 is a short-lived peptide, a review having given a plasma half-life of about two minutes; at the same time, certain experimental studies have found that the biological responses lasted considerably longer than the amount of peptide present in the circulation.
The fact that there is a difference between circulating exposure and a downstream biological response is an important question in pharmacological research.
It does not follow that all biological endpoints will vanish at the same rate just because a plasma half-life is short. Activation of receptors, intracellular signalling, transcriptional changes and downstream cellular responses may take place on different timescales.
As a result, the ARA-290 studies have to separate pharmacokinetic measurements from pharmacodynamic endpoints since sampling time, tissue distribution, assay sensitivity and the choice of endpoint can all affect the interpretation.
Current Research Limitations
The ARA-290 has been studied in a number of biological systems, but the body of evidence is not consistent.
One limitation is that receptor biology remains an area of scientific discussion. While several studies support a role for the EPOR/β-common receptor system, other work has questioned whether the proposed receptor components form a direct physical complex under all experimental conditions.
A second limitation concerns model translation. Results obtained from cultured cells, genetically modified animals or experimentally induced tissue injury cannot automatically be extrapolated to unrelated biological conditions.
A third issue is peptide characterization. Small differences in sequence, terminal modification, purity or analytical identity can affect receptor interactions and experimental reproducibility.
For all these reasons, the research involving ARA-290 should be understood by taking into account the precise peptide identity, the experimental model, the manipulation of the receptor, the analytical methods used, and the endpoints that were measured.
Why ARA-290 Remains Relevant to Peptide Research
ARA-290 provides an interesting example of how peptide research can move beyond the activity of an entire protein.
Rather than reproducing full-length EPO, researchers designed a much smaller peptide based on structural information from the parent molecule. This creates an experimental system for examining receptor-selective signalling and the relationship between receptor activation and downstream cellular responses.
The broader research value lies in the experimental questions surrounding peptide structure, receptor specificity, signalling pathways and biological response.
This makes ARA-290 particularly relevant to research involving peptide-receptor interactions, cytokine signalling, neuroinflammation, cellular stress responses and experimental models of tissue injury.
Research-Use-Only Perspective
ARA-290 should be discussed in a research context rather than as a product for treating pain, neuropathy or other medical conditions.
Published studies can be useful for understanding receptor biology, experimental design and molecular mechanisms, but research findings should remain separated from claims about human therapeutic outcomes.
For laboratory work, researchers should focus on verified peptide identity, analytical characterization, experimental controls and the specific biological question being investigated.
People who are interested in peptide structure, receptor signalling and experimental peptide biology can find the wider variety of research products available by going to the.
View research materialsThe category offers a starting point for the examination of peptide compounds on the basis of their scientific identity and the intended laboratory research context.
View research materialsFAQs
References
- Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015 Jul;151:32-40. doi: 10.1016/j.pharmthera.2015.02.005. Epub 2015 Feb 26. PubMed ↗
- Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14907-12. doi: 10.1073/pnas.0406491101. Epub 2004 Sep 29. PubMed ↗
- Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014 Feb 16;10:13. doi: 10.1186/1744-8069-10-13. PubMed ↗
- Wang RL, Yang ZH, Huang YY, Hu Y, Wang YL, Yan F, Zheng YM, Han ZP, Fan JF, Tao Z, Zhao HP, Li SJ, Luo YM. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. CNS Neurosci Ther. 2024 Mar;30(3):e14676. doi: 10.1111/cns.14676. PubMed ↗
- Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the innate repair receptor to treat neuropathy. Pain Rep. 2016 Aug 9;1(1):e566. doi: 10.1097/PR9.0000000000000566. PubMed ↗
- Cheung Tung Shing KS, Broughton SE, Nero TL, Gillinder K, Ilsley MD, Ramshaw H, Lopez AF, Griffin MDW, Parker MW, Perkins AC, Dhagat U. EPO does not promote interaction between the erythropoietin and beta-common receptors. Sci Rep. 2018 Aug 20;8(1):12457. doi: 10.1038/s41598-018-29865-x. Erratum in: Sci Rep. 2019 May 21;9(1):7851. doi: 10.1038/s41598-019-43988-9. PubMed ↗
- Hache G, Garrigue P, Bennis Y, Stalin J, Moyon A, Cerami A, Brines M, Blot-Chabaud M, Sabatier F, Dignat-George F, Guillet B. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability. Shock. 2016 Oct;46(4):390-7. doi: 10.1097/SHK.0000000000000606. PubMed ↗
